Steven Frank insider trades

Open-market stock purchases and sales by Steven Frank, Director at Biocryst Pharmaceuticals Inc, from SEC Form 4 filings since Sep 10, 2013.

Track record: 100% of 1 scored buy are up 5% or more since purchase, averaging +108%.

Recent trades

DateStockTradeValue
Aug 31, 2026BCRX Biocryst Pharmaceuticals IncBought (not open market)$12.5K
Jun 11, 2026BCRX Biocryst Pharmaceuticals IncBought (not open market)—
Jun 11, 2026BCRX Biocryst Pharmaceuticals IncBought (not open market)—
May 29, 2026BCRX Biocryst Pharmaceuticals IncBought (not open market)$11.2K
Mar 13, 2026PGEN Precigen, IncBought (not open market)—
Mar 10, 2026PGEN Precigen, IncBought (not open market)$50K
Mar 10, 2026PGEN Precigen, IncBought (not open market)—
Mar 10, 2026PGEN Precigen, IncBought (not open market)—
Feb 27, 2026BCRX Biocryst Pharmaceuticals IncBought (not open market)$11.2K
Nov 28, 2025BCRX Biocryst Pharmaceuticals IncBought (not open market)$11.2K

Companies traded

  • BCRX Biocryst Pharmaceuticals Inc: other filings, last Aug 31, 2026
  • PGEN Precigen, Inc: 1 buy, last Mar 13, 2026
  • XON Intrexon Corp: other filings, last Mar 23, 2018

Get free alerts when Steven Frank files a new trade →